Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

(2022) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial

(2022) Satoshi Ebata et al.   Lancet Rheumatology

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

(2021) Kristin B Highland et al.   Lancet Respiratory Medicine

Prognosis and treatment of myositis‐associated severe interstitial lung disease: A descriptive study using a nation‐wide inpatient database in Japan

(2021) Hiroki Furuya et al.   ARTHRITIS CARE & RESEARCH

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

(2021) Jürgen Behr et al.   Lancet Respiratory Medicine

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

(2021) Sharon A. Chung et al.   Arthritis & Rheumatology

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial

(2021) Satoshi Ebata et al.   Lancet Rheumatology

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

(2021) Jérôme Avouac et al.   Lancet Rheumatology

2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases

(2020) Yoshiya Tanaka et al.   Modern Rheumatology

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

(2019) Oliver Distler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti‐topoisomerase I‐positive systemic sclerosis‐associated interstitial lung disease

(2019) Satoshi Ebata et al.   JOURNAL OF DERMATOLOGY

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

(2019) Kevin R. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

(2019) Toby M Maher et al.   Lancet Respiratory Medicine

Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement

(2019) Brian L. Graham et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

OUP accepted manuscript

(2018)   RHEUMATOLOGY

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial

(2017) Peter Saunders et al.   Trials

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis

(2017) Nicole S. Goh et al.   Arthritis & Rheumatology

2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups

(2017) Ingrid E. Lundberg et al.   Arthritis & Rheumatology

EQ-5D and the EuroQol Group: Past, Present and Future

(2017) Nancy J. Devlin et al.   Applied Health Economics and Health Policy

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

(2016) M Yates et al.   ANNALS OF THE RHEUMATIC DISEASES

Update of EULAR recommendations for the treatment of systemic sclerosis

(2016) Otylia Kowal-Bielecka et al.   ANNALS OF THE RHEUMATIC DISEASES

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

(2016) Donald P Tashkin et al.   Lancet Respiratory Medicine

Forced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and Nintedanib

(2015) Banu A. Karimi-Shah et al.   NEW ENGLAND JOURNAL OF MEDICINE

The diagnosis and classification of mixed connective tissue disease

(2014) Chiara Tani et al.   JOURNAL OF AUTOIMMUNITY

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

(2013) Frank van den Hoogen et al.   ANNALS OF THE RHEUMATIC DISEASES

The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease

(2013) Amit S. Patel et al.   RESPIRATORY MEDICINE

Rituximab in severe, treatment-refractory interstitial lung disease

(2013) Gregory J. Keir et al.   RESPIROLOGY

Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy

(2012) Gregory J. Keir et al.   EUROPEAN RESPIRATORY JOURNAL

The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire

(2012) Amit S Patel et al.   THORAX

Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: A series of 107 patients

(2011) I. Marie et al.   ARTHRITIS AND RHEUMATISM

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

(2010) A. J. Tyndall et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

(2010) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

(2010) Rachel B. Jones et al.   NEW ENGLAND JOURNAL OF MEDICINE

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

(2009) Dimitrios Daoussis et al.   RHEUMATOLOGY